Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit
Details : The presentation will highlight the continued safety and psychometric activity of the company's lead clinical molecule, SXC-2023, a drug designed to restore cognitive control over repetitive, maladaptive behaviors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2020
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Celerion | Baylor College of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Details : SXC-2023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Disruptive, Impulse Control, and Conduct Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2019
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Celerion | Baylor College of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study in Patients With Trichotillomania
Details : SXC-2023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Trichotillomania.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2019
Lead Product(s) : SXC-2023
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SXC-2023
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SXC-2023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2018
Lead Product(s) : SXC-2023
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SXC-2023
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SXC-2023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2017
Lead Product(s) : SXC-2023
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
